Current status of Continuous Renal Replacement Therapy (CRRT) vs Slow Low Efficient Daily Dialysis/Extended Duration Dialysis (SLEDD/EDD) as Renal Support System for Hemodynamically Unstable Patients

2005 ◽  
Vol 2 (3) ◽  
pp. 224-229
Author(s):  
Sanjiv Jasuja
2019 ◽  
pp. S39-S45
Author(s):  
Evelyn Obando ◽  
Eliana López ◽  
David Montoya ◽  
Jaime Fernández Sarmiento

Continuous renal replacement therapy (CRRT) is a well-established supportive treatment for acute kidney injury in pediatric intensive care units. Knowing its basic aspects allows a rational approach to therapy, making this therapeutic option a more adaptable treatment for individual patient. Different strategies may be used in the same child, depending on the clinical situation and the changes that may present throughout the clinical course. This article explains the physical principles, modalities of continuous renal replacement therapies, and membrane and filter characteristics in order to better understand the transmembrane transport of fluids and solutes in continuous renal replacement therapy.Abbreviations: CRRT= Continuous renal replacement therapy; SCUF = Slow continuous ultrafiltration therapies; FF = Filtration fraction; CVVH = Continuous venovenous hemofiltration; AKI = Acute kidney injury; CVVHD = Continuous venovenous hemodialysis; CVVHDF = Continuous venovenous hemodiafiltration; SLEDD = Sustained low-efficiency daily dialysis, EDDf = Extended daily dialysis with filtration, PDIRRT = Prolonged daily intermittent renal replacement therapyCitation: Obando E, López E, Montoya D, Fernández-Sarmiento J. Continuous renal replacement therapy: understanding the foundations applied to pediatric patients. Anaesth Pain & Intensive Care 2018;22 Suppl 1:S39-S45


2020 ◽  
Vol 49 (4) ◽  
pp. 490-495
Author(s):  
Ian Baldwin ◽  
Daryl Jones ◽  
Paula Carty ◽  
Nigel Fealy

Continuous renal replacement therapy (CRRT) is intended to function continuously and is prescribed for this outcome. Anticoagulants may not always be used. Clotting and clogging within the CRRT filter stopping therapy occurs with a variability in the total elapsed time associated. This is commonly known as the circuit or filter “life”. It is very useful and important to record this time at the bedside and refer to this as a measure of success and quality. Filter life (i.e., hours) is reported in many reports investigating CRRT but is not well understood or clear for when this is considered inadequate and clinical review strategies should be considered. Failure before 8 h could be associated with inadequate renal support and “therapy”. Anticoagulation is the key intervention to prolong filter function; however, the extracorporeal circuit design and set up, access catheter profile and insertion site, CRRT machine settings, and the human interface operating CRRT are always important and the only consideration to prevent failure when no anticoagulation is mandated for CRRT.


Author(s):  
Shigeto Oda ◽  
Tomohito Sadahiro ◽  
Yo Hirayama ◽  
Masataka Nakamura ◽  
Eizo Watanabe ◽  
...  

2017 ◽  
Vol 28 (1) ◽  
pp. 31-40 ◽  
Author(s):  
Hildy Schell-Chaple

Continuous renal replacement therapy (CRRT) was introduced more than 40 years ago as a renal support option for critically ill patients who had contraindications to intermittent hemodialysis and peritoneal dialysis. Despite being the most common renal support therapy used in intensive care units today, the tremendous variability in CRRT management challenges the interpretation of findings from CRRT outcome studies. The lack of standardization in practice and training of clinicians along with the high risk of CRRT-related adverse events has been the impetus for the recent expert consensus work on identifying quality indicators for CRRT programs. This article summarizes the potential complications that establish CRRT as a high-risk therapy and also the recently published best-practice recommendations for providing high-quality CRRT.


2016 ◽  
Vol 49 (11) ◽  
pp. 733-741
Author(s):  
Shigeo Negi ◽  
Daisuke Koreeda ◽  
Sou Kobayashi ◽  
Yu Iwashita ◽  
Takashi Shigematsu

Sign in / Sign up

Export Citation Format

Share Document